Connect with us

HEALTH

Reptogel Mosquito Repellant Launched in Sango

Published

on

The malaria fact sheet recently published by the United States embassy in Nigeria confirmed that there are an estimated 100 million cases with over 300,000 deaths per year. The report stated that malaria contributes to an estimated 11% of maternal mortality in the country.

This alarming statistics may have triggered Drugfield Pharmaceutical Limited in Sango Ota and Tiptop Nigeria Limited to join forces in combating malaria as they signed a partnership deal to launch Reptogel Mosquito and Insect Repellant Gel.

Speaking at the official signing of the partnership, held recently at the Sango Ota head office of Drugfield Pharmaceutical, Pharm. Olakunle Ekundayo, group managing director (GMD), Drugfield, expressed confidence that the partnership would be fruitful, saying the reason for the partnership boils down to the issue of confidence and trust, coupled with the experience in sales and marketing that Tiptop would bring to the table.

The Drugfield boss further explained that the signing of the MOU represented a symbiotic and mutual relationship aimed at putting the patient first, adding that through the new partnership, more people in the country would easily get access to Reptogel Mosquito and Insect Repellant Gel, anywhere in the country.

His words: “Drugfield is a wholly Nigerian company and same goes for Tiptop, so if we team up and make a success, then it’s better for us, rather than looking for an outsider when we have our own around us.

“We also know that Tiptop is a reliable company because its chief executive director, Pharm. Gbenga Falabi, is a seasoned marketer and he has been successful with so many products in the past, so we are hopeful that this won’t be an exception’, he said.

In his address, Gbenga Falabi who represented Tiptop Nigeria Limited, -sole marketing communications firm for Reptogel revealed that Tiptop’s relationship with Drugfield had been on for years, adding that the birth of Tiptop’s about two years ago was a milestone as it happened shortly after he left Greenlife Pharmaceuticals Limited in 2018.

According to Falabi, a former general manager of Greenlife Pharmaceuticals and past national chairman, Association of Industrial Pharmacists of Nigeria (NAIP), Drugfield is a reputable pharmaceutical company with a vision to eradicate diseases in the country and beyond through provision of top quality, affordable and available pharmaceuticals.

He said Tiptop, being a company whose objective is to help keep companies alive and well, was optimistic that the partnership aside being profitable would help save more lives from being destroyed by malaria.

According to the former NAIP boss, the burden of malaria in the country in spite of the progress made so far in combating the disease is quite alarming, noting that Nigeria still rank among countries with highest deaths as about 480, 000 deaths occur yearly in Africa alone, with Nigeria taking over 60 percent of it.

He added that Drugfield has taken a step in the right direction with the production of Reptogel Mosquito and Insect Repellant Gel, saying malaria is endemic in the country as it poses major challenge to the country and as well impedes human and infrastructural development.

Speaking on the product, Falabi, said Reptogel Mosquito and Insect Repellant Gel, is ready to protect Nigerians from mosquitoes by creating a ‘No Mosquito Zone’ for its users, adding that with each application, a consumer could enjoy up to 8 hours protection which he said was not possible with other mosquito gels that have flooded the market.

“The message is that when people are going for vigil, they should use Reptogel, children in hostels, those in schools or anybody that stay late in the evening when mosquitoes are active needs the product, he said.

Speaking about its affordability, he said it is very cheap as a piece of it costs around three hundred naira or thereabout in shops, adding that the company, Drugfield is planning to come up with 85gramms pack which is designed for the family and it will soon be unveiled in the course of the year.

GidiNews is exclusively designed to cover and report Lagos, Nigeria's commercial capital city. We bring you news updates, reports, opinions and analyses in Politics, Business, Sports, Entertainment, Crime, Health and Education among others. GOT NEWS FOR US? Reach us: +2349090870065, +2348055441309

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published.

HEALTH

Court dismisses suit challenging Lagos Okada ban

Published

on

By

The Federal High Court sitting in Lagos, has dismissed a suit by a Lagos resident challenging the Lagos State Government’s restriction of commercial motorcycles from some of its roads.

Justice Akintayo Aluko held that the applicant, Julius Ajibulu, “failed woefully” in his bid to reverse the ban which has been in place since 2018.

The judge held that Ajibulu also failed, among others, to establish that the Lagos State government has no power to ban the operation of tricycles and motorcycles in respect of the designated roads in the state.

The judgment followed the Plaintiff’s suit marked FHC/L/CS/1389/2020 against the Governor of Lagos State, Attorney General of Lagos State, Commissioner for Transportation and Speaker, Lagos State House of Assembly as 1st to fourth defendants respectively.

Lagos State had on Monday January 27, 2020 moved against commercial motorcycles (Okada) and tricycles (Keke NAPEP), proscribing their operations in six Local Government Areas (LGAs), nine Local Council Development Areas (LCDAs) and 10 major highways across the state with effect from February 1, 2020.

The government directed security operatives to embark on a total enforcement of the State’s Transport Sector Reform Law of 2018 to immediately address the chaos and disorderliness created by illegal operations of Okada and tricycle riders in restricted areas.

The government also banned Okada and tricycles from plying 40 bridges and flyovers across the State.

But Ajibulu contended that sections 15, 16, 19, 46 and 68 of the Lagos State Transport Sector Reform Law 2018, violated sections 1,4,5, items 11 and 63 of the exclusive legislative list in part 1, second schedule to the constitution.

He argued that it also offended section 10(3)(t) of the Federal Road Safety Commission (Establishment) Act, section 92 of the Federal Road Safety Commission (Establishment) Act, and section 1 of the Federal Highways Act/Subsidiary Legislation Cap F13, LFN, 2004.

In his judgment delivered on January 12, 2023, a copy of which was obtained by The Nation yesterday, the judge agreed with the defendants that Ajibulu’s case did not hold water.

Justice Aluko agreed, as Ajibulu argued, that section 4(3) of the Constitution gives the National Assembly power to make laws with respect to any matter in the exclusive legislative list to the exclusion of the Houses of Assembly of States.

He held: “The Plaintiff has referred the court to items 11 and 63 of part 1 in the exclusive legislative list which have to do with construction, alteration and maintenance of such roads as may be declared by the National Assembly to be Federal trunk roads and traffic on Federal trunks roads.

“The Plaintiff has however failed to show to the court that all the over 40 roads and bridges listed in his reliefs are Federal trunk roads declared by the National Assembly as provided under items 11 and 63 in the Exclusive Legislative list under part 1 of the 2nd schedule to the Constitution.

“The Plaintiff failed to establish before the court that the provisions of sections 15, 16, 19, 46 and 68 of the Lagos State Transport Sector Reform Law 2018 were made to apply to the operations of tricycles and motorcycles in respect of the over 40 roads mentioned in his reliefs.”

The judge noted that Ajibulu “failed woefully to prove his entitlement to the reliefs stated in the originating summons.

“The Plaintiffs has failed to establish that the State House of Assembly has no power to have made the law in contention and has equally failed to establish that the State government has no power to ban the operation of tricycles and motorcycles in respect of the designated roads in Lagos State.

“Granting the reliefs of the Plaintiff without placing any credible evidence before the court is tantamount to preventing the State House of Assembly from making laws for the peace, order and good government of the state or any part thereof and engaging in such venture will undoubtedly constitute a violation of and amount to overrunning section 4(7)CFRN, 1999 (as amended).

The Plaintiff failed to establish before the court that the provisions of sections 15, 16, 19, 46 and 68 of the Lagos State Transport Sector Reform Law 2018 were made to apply to the operations of tricycles and motorcycles

“That is forbidden and this court will not venture into such unconstitutional enterprise.

“Coming from the foregoing, the Plaintiff has failed to prove his case by credible evidence as required by law. Accordingly, the case of the Plaintiff lacks merit and same is hereby dismissed.”

Continue Reading

HEALTH

“Nigeria to increase effort in fighting sub-standard products”

Published

on

By

By Michael Dibie

Minister of state for Health, Joseph Ekumankama has reiterated that the government of Nigeria will continue to fight the activities of sub-standard products in the health sector which has over the years impeded operations in the industry. The minister made the promise at the West African Postgraduate College of Pharmacists (WAPCP)/ The National Institute for Pharmaceutical Research and Development (NIPRD) scientific workshop held in Abuja.

According to the minister, the government will increase its effort in fighting the menace through the activities of the National Agency for Food and Drug Administration (NAFDAC) and Standard Organisation of Nigeria (SON),

“Sub-standard product has been a fight we have been fighting for years and we will continue to do so, it may not stop today but we will support the agency to continue to fight it, he said”

Speaking on the workshop, he notated that auspicious event is aimed at bringing together critical stakeholders within the pharmaceutical sector to review the existing capacities for the local production of API in Nigeria and develop strategies to accelerate the process in the West African Region, leveraging on the African Free Continental Trade Area (AfCFTA).

According to the minister, there are still significant barriers to access to quality medicines and healthcare provision to the Nigeria population.

“The situation where there is no single pharmaceutical company that produces any APIs or pharmaceutical excipients locally is no longer tolerable. All of the APIs used by the industries in Nigeria are imported from India, China, the USA and Germany, he added”

In a keynote address, the Director General (NIPRD), Dr. Obi Peter Adigwe said that NIPRD has proffered solutions both national and international willing to bring in innovations that can help Africa and taking Nigeria projects to the next level.

“We train people in the area of traditional medicines through harnessing local ingredients and creating jobs. Our multi-billion Laboratory is almost completed and new innovations in the health sector are being looked into in other to access new ways or avenues of doing things, he added’
He also noted that NIPRD will continue to focus on innovative projects for the people that will encourage job creation and access to quality health delivery

President of the West African Postgraduate College of Pharmacists, Prof. Cecilia Igwilo called on developed countries to support the sector in getting all the active ingredients from the research table into the pilot table to production. She urged the agencies to partner for developmental research projects.

‘If we have active ingredients, we want to push 1-3, we must make sure that we patted that through the proper organization so that it will be there for the next 10 years depending on the duration in other to recover and ensure that no other person does what we are doing, she said”

Speaking on the effect of the Covid-19 on Africa, Chief of Party, USP, MOPA ESUGA said. The African continent was worst hit by scarcity of essential medication and needed medical supplies on account of export bans placed by India and China.

According to him, the manufacture of APIs is still at a modest level in Sub-Saharan Africa and South Africa taking the lead.
“I believe my role today is not just about the science of API manufacturing but agenda-setting that should galvanize the key stakeholders towards strategies that make for the manufacture of APIs in the West Africa sub-region”

It should be noted that in sub-Saharan Africa (SSA), where the overall pharmaceutical market size is worth US$ 20 billion annually, the production of life-saving medicines is furthermore concentrated in very few countries: 50 per cent of pharmaceutical manufacturing takes place in South Africa and an additional 40 per cent in Nigeria, Ghana, Kenya and Uganda combined.

The overall African Pharmaceutical sector is worth US$ 30 billion per annum. However, the pharmaceutical manufacturing sector in Africa contributes to only 25-30 per cent of the continent’s needs.

NIPRD is a Federal Government Parastatal under the Federal Ministry of Health. The institute was designated a center of Excellence in the African sub-region in research and development of drugs and vaccines, phytomedicines, and diagnostic towards improving the health and well-being of Nigerians and mankind.

Continue Reading

HEALTH

“This is why you may have contacted Omicron without knowing” -WHO

Published

on

The Omicron COVID-19 variant is more transmissible than the Delta strain and reduces vaccine efficacy but causes less severe symptoms according to early data, the World Health Organisation said Sunday.

The Delta variant, first identified in India earlier this year, is responsible for most of the world’s coronavirus infections.

But South Africa’s discovery of Omicron – which has a large number of mutations — last month prompted countries around the world to impose travel bans on southern African countries and reintroduce domestic restrictions to slow its spread.

The WHO said Omicron had spread to 63 countries as of December 9. 

The faster transmission was noted in South Africa, where Delta is less prevalent, and in Britain, where Delta is the dominant strain.

But it stressed that a lack of data meant it could not say if Omicron’s rate of transmission was because it was less prone to immune responses, higher transmissibility, or a combination of both.

Early evidence suggests Omicron causes “a reduction in vaccine efficacy against infection and transmission”, the WHO said in a technical brief.

“Given the current available data, it is likely that Omicron will outpace the Delta variant where community transmission occurs,” it added.

Omicron infections have so far caused “mild” illness or asymptomatic cases, but the WHO said the data was insufficient to establish the variant’s clinical severity.

South Africa reported Omicron to the WHO on November 24. Vaccine manufacturers Pfizer/BioNTech last week said three doses of their jabs were still effective against Omicron.

Countries with sufficient vaccine supplies such as Britain and France have encouraged their populations to receive a third “booster” jab to fight Omicron.

(AFP) 

Continue Reading

Most Read